⚔️ CROX vs EEFT vs NVO vs PDD

📋 Executive Summary

Seven legendary investors debated which of four deeply discounted businesses — Crocs (CROX), Euronet Worldwide (EEFT), Novo Nordisk (NVO), and PDD Holdings (PDD) — they would own for the next decade. All four trade under 10× earnings, a compression rarely seen across businesses of such varied quality. The central question: does biological lock-in, fashion momentum, payment infrastructure, or Chinese platform scale offer the most durable compounding at these prices?

• 🏆 Winner: Novo Nordisk (NVO) — 3 votes. Patients who discontinue semaglutide regain two-thirds of their lost weight within a year — a physiological switching cost no contract can replicate. At 10× earnings, the market implies 6% growth for a business serving fewer than 2% of 890 million eligible obesity patients worldwide.

• 🥈 Runner-up: Euronet Worldwide (EEFT) — 2 votes. A 32-year founder-CEO compounding FCF per share at 17% annually, with payment infrastructure across 40 countries, trading at 9.5× earnings.

• ⚠️ Dividing risk: Whether Novo's U.S. market share losses to Lilly's tirzepatide signal a temporary supply mismatch or a permanent competitive shift that erodes the duopoly premium.

• 💡 Surprising insight: The market is pricing Crocs for negative annual growth — roughly -2% implied — while the company grew international revenue 11% last year and China surged 30%.

• 🔢 Most decisive metric: NVO's 43% ROIC, sustained for 14 consecutive years, convinced three investors that the business quality justified paying a modest premium over cheaper alternatives.

The bottom line: when human physiology creates the switching cost, the margin of safety is biological rather than mathematical. But the council's dissenters — holding Crocs at 4.7× and Euronet at 9.5× — may yet prove that paying less for adequate quality beats paying fair for excellence.

PART 1: THE CONTENDERS

Buffett: "Let me frame what we're looking at. Crocs makes foam clogs at 61% gross margins — a $55 shoe that costs $15 to produce. Euronet runs the invisible plumbing of cross-border payments, operating 54,000 ATMs and the world's third-largest remittance network across forty countries. Novo Nordisk sells weekly injections to 46 million chronic patients whose own biology punishes them for stopping. And PDD built a digital bazaar where Chinese factories sell directly to 900 million consumers, bypassing the middlemen who typically extract most of the value chain."

"Four businesses, all under 10× earnings — that almost never happens in a single room. But cheap and good are different words. So let me ask the question that matters: which of these can I predict with confidence in 2036?"

PART 2: BUSINESS QUALITY & MOATS

Munger: "Warren, I'll invert your question because it cuts deeper. Instead of asking which one is predictable, ask which one cannot be disrupted by a competitor willing to spend $5 billion and a decade of effort. Novo passes that test decisively — you'd need clinical trials, FDA approval, manufacturing at pharmaceutical scale, and a global salesforce just to become the third player in a near-duopoly. Lilly has managed it, barely, and nobody else is close. Crocs? A well-funded shoe company with one talented designer can launch a competing clog in eighteen months. Euronet's ATMs face displacement from banking apps. PDD's marketplace battles Alibaba, JD, and Douyin daily. The quality of the competitive barrier here varies enormously."

Tepper: "Charlie, I respect the framework, but you're confusing durability with profitability at this price. Novo's moat characteristics are real — I don't argue that. But the stock fell 50% from its highs for a real reason: Lilly's tirzepatide is capturing share every quarter. Novo grew U.S. GLP-1 diabetes sales just 5% in 2025 while the overall market grew over 10%. That's not a supply constraint anymore — that's a competitive problem showing up in the actual prescription data. When Novo's own CEO acknowledges that gains were 'partially countered by market share losses,' you're hearing an admission that the duopoly dynamics are shifting. The question is whether Mr. Market has overreacted. At 10× earnings, I think yes — but let's not pretend the competitive position is unchanged."

Kantesaria: "David, you just strengthened my case for avoiding pharma entirely. The moat depends on pipeline execution, not structural inevitability. Compare that to the payment networks I own — every digital transaction pays Visa or Mastercard whether the economy booms or crashes, and that toll is embedded in infrastructure that took decades to build. With Novo, biological switching costs lock patients into GLP-1 therapy as a class, not into Novo specifically. A physician writes a new prescription for Lilly's Mounjaro, the patient walks to the same pharmacy, and their weight loss continues without interruption. That's fundamentally different from my holdings where no substitute pathway exists at all."

Vinall: "Dev, I hold Novo in my portfolio, so let me push back. The distinction between class loyalty and brand loyalty matters less than you think when one company has a 14-year head start in physician relationships and manufacturing know-how. What it actually takes for a doctor to switch a stable patient is nontrivial — titration schedules need resetting, prior authorization paperwork starts from scratch, and side-effect monitoring begins again. But here's why the smaller names at this table interest me more: Novo at $172 billion needs to become a $500 billion company for me to earn 12% annualized. Crocs at $4.5 billion or Euronet at $3.0 billion? The compounding math is far more forgiving at those sizes."

Pabrai: "Robert, now you're speaking my language. Crocs at 4.7× earnings is the most interesting setup on this table, and it reminds me of when I bought auto dealerships during COVID — businesses generating real cash flow at crisis multiples because everyone assumed they were dying. The market is pricing Crocs for permanent decline, but the company grew international revenue 11% last year, China surged 30% off a small base representing only 8% of brand sales, and management retired 10% of the float through buybacks. They're generating roughly $15 per share in free cash flow on a $76 stock. Even if the brand slowly fades, I'm collecting an enormous cash yield while I wait. Downside at these multiples is maybe 30%; upside if the brand holds is 5-8× over a decade."

Prasad: "Mohnish, I hear the math, but you're skipping the evolutionary question — and that's the one that decides whether those cash flows actually persist for ten years. Crocs nearly went extinct once already, collapsing from 23% ROIC to 2% in a single year when fashion sentiment shifted in 2012-2013. The species survived, but only through a complete management overhaul and multi-year turnaround. Fashion operates in what I'd call a fast-change environment, where competitive advantages can reverse in quarters. Crocs in 2026 reminds me of Coach — now Tapestry — in 2014: dominant share, luxury-adjacent margins, fiercely loyal base. Then Michael Kors ate their lunch. The stock fell 60% and took five years to recover."

Buffett: "Pulak's Coach parallel is exactly what keeps me up at night about Crocs. But let me offer a different historical echo for Novo. It reminds me of Moody's after the financial crisis in 2009. Everyone said the rating agencies were broken, the stock fell 75%, and yet the structural position was unchanged because bond issuers had to use them — there was no alternative pathway. Novo's patients face a similar compulsion. Stop the injections, regain two-thirds of the weight. That biological reality is the closest thing to a regulatory mandate I've ever seen in healthcare. Now, Moody's went on to return 20× over the next fifteen years. The question is whether Novo's competitive dynamics — with Lilly gaining ground — make this a weaker parallel than it appears."

Munger: "Warren, your Moody's comparison works in one direction and fails in another. Moody's had no legitimate competitor — it was a pure duopoly with S&P where both parties benefited from the arrangement. Novo faces a genuine rival in Lilly whose tirzepatide is arguably the superior molecule. That matters. But let me redirect to what I think everyone is underweighting: the demand side of this equation. We keep debating whether Novo holds share against Lilly, but the denominator — the total addressable patient pool — is barely scratched. Fewer than 2% of eligible patients are treated globally. Two companies fighting over a market growing 30% annually is not a zero-sum game. It's a bonanza where both can win."

Kantesaria: "Charlie, while you're building the Novo case, I want us to honestly assess PDD, because the economics are remarkable even if I can't own it. This company built $57 billion in revenue requiring just 0.24% of sales in capital expenditure — that efficiency rivals anything in my portfolio. The team-purchase model turned buyers into unpaid salesforce, creating viral customer acquisition at near-zero cost. But the fatal flaw for my framework is simple: no mandatory checkpoint exists. A Chinese consumer can shop across Alibaba, JD, or Douyin without penalty, and Beijing has shown willingness to reshape platform economics overnight. Alibaba's 'common prosperity' restructuring in 2021 destroyed $500 billion in market value in a year. PDD faces identical political risk."

Tepper: "Dev, that's exactly the setup I look for — when smart money like Li Lu, Duan Yongping, and Norbert Lou are accumulating shares that Western consensus has abandoned. These aren't tourists. Li Lu managed Berkshire's China investments for years. The reflexive disconnect between what China-focused experts are buying and what institutional mandates force selling is where I make money. PDD sits on $58 billion in cash — 40% of the market cap — and the domestic business alone earns 24% ROIC on essentially zero invested capital. But here's the second-order effect nobody models: if de minimis tariff changes kill Temu's U.S. business, those resources don't evaporate. They get redeployed to Southeast Asia and Latin America, where the regulatory environment is friendlier and the competitive landscape is wide open."

PART 3: FINANCIALS & TRACK RECORD

Vinall: "David, before we get carried away with PDD's optionality, let me walk through the math that matters for a ten-year hold, starting with Euronet. Michael Brown has run this business for 32 years as founder-CEO — he passes my sledgehammer test without hesitation. Revenue compounded at 10% annually for 14 consecutive years, but the real story is FCF per share compounding at 17% because buybacks retired 15% of outstanding shares. Starting from $7 EPS at 12% historical growth, ten years delivers roughly $21.74. Apply a 15× exit multiple — modest for payment infrastructure — and you reach $326 per share, about 4.9× your money or 17% annualized. That clears my hurdle rate without heroic assumptions, and the business has three distinct revenue engines — EFT processing, money transfer, and epay — so if one segment stumbles, the others carry the load. But what convinces me this moat is widening, not just wide, is the EFT segment's transformation: merchant acquiring EBITDA grew 32% last year as Brown pivots from hardware-heavy ATM ownership to software-driven payment processing."

Pabrai: "Robert, your Euronet math is solid, but the exit multiple does the heavy lifting — you're assuming a market re-rating for a company that's traded at a chronic discount. Let me show you why Crocs offers far superior asymmetry. Starting from $16 adjusted EPS — I'm using normalized earnings excluding the HEYDUDE impairment — at the 12% historical growth rate, ten-year EPS reaches roughly $49.69. Even at a 12× exit multiple, still a discount to the S&P 500, the stock reaches $596. That's 7.9× my investment, or 23% annualized. But here's the asymmetric setup: even if growth slows to half that rate — just 6% annually — I still reach $344, or 4.5× my money. That's 16% annualized in the bear case. The reason this works is the brutally low starting multiple. At 4.7×, I'm not paying for the brand, the international expansion, or China. I'm paying for the existing cash flow stream and getting everything else for free."

Buffett: "Mohnish, I have to challenge your exit multiple. You're giving Crocs 12× in perpetuity, which assumes the market eventually treats this as a normal business. But the market trades it at 4.7× because the earnings are unpredictable — North America revenue fell 7% last year, operating margins compressed for the fourth straight year from 29.5% to 22.3%, and management took a half-billion-dollar impairment on the HEYDUDE acquisition they paid $2 billion for in 2022. The real bear case isn't 6% growth — it's a repeat of 2012-2013, when ROIC collapsed from 23% to 2% in a single year and no amount of entry-price discipline saved you. Think one step further about the growth quality: Crocs brand international expansion is genuine, but North America is the profit engine, and it's contracting. If the core erodes while management pours capital into stabilizing a HEYDUDE brand that's declining 14% annually and just consumed $500 million in impairments, you're watching capital allocation destroy per-share value."

Munger: "Warren just described why the growth quality at Crocs makes me deeply uncomfortable. Contrast it with Novo's growth engine. Novo's obesity franchise went from DKK 6 billion to DKK 82 billion in six years — a 14× increase — driven entirely by organic demand from a single product family with biological lock-in. Zero acquisitions required. Compare that capital allocation record to Crocs, whose signature deal was the HEYDUDE acquisition that management refuses to divest despite obvious failure. Novo's growth comes from expanding the pool of treated patients as manufacturing capacity ramps. That's driven by epidemiology — the obesity rate isn't cyclical, it accelerates. The second-order implication is powerful: as more patients get treated and physicians accumulate experience, the standard of care shifts, and not prescribing becomes the medical outlier. That flywheel doesn't exist for foam clogs."

Kantesaria: "Charlie, you've described why Novo's growth is higher quality, but the capital allocation picture complicates things. CapEx surged from DKK 7.4 billion in 2021 to DKK 90.1 billion in 2025 — roughly a 12× increase. Free cash flow turned negative in 2024 before recovering to approximately DKK 40 billion in 2025. Total debt quintupled from DKK 27 billion to DKK 131 billion, while cash reserves fell to DKK 498 million. This is a company spending aggressively to build capacity serving 10× the current patient base. The second-order chain here is critical: if CagriSema delivers strong Phase 3 data and CapEx normalizes by 2028, free cash flow inflects sharply upward and the current multiple looks like a gift. But if Lilly's pipeline proves superior while Novo sits mid-build-out, those factories run at 40% utilization and DKK 131 billion in debt becomes an anchor, not a bridge. That binary outcome is precisely why I avoid pharma."

Prasad: "Dev, that's the right risk framework, but the counter-chain deserves equal weight. Novo has been scaling pharmaceutical manufacturing for a century — this isn't their first major capacity build. If the build-out succeeds, the installed base of sterile fill-finish facilities becomes its own competitive barrier. A new entrant wanting to match those production volumes would need to replicate DKK 180 billion in cumulative CapEx across dozens of facilities, a process that takes seven to ten years even with unlimited funding. The first-order effect of massive CapEx is compressed returns today. The second-order effect is a manufacturing moat that locks out everyone except Lilly for the foreseeable future."

Tepper: "Pulak, you're making the bull case for Novo, but let me bring us back to what the market is actually paying for PDD. This company generated RMB 112 billion in net income last year — roughly $15 billion — on virtually zero invested capital. But the growth quality question is urgent: strip out Temu's international expansion, and the domestic Pinduoduo business is growing mid-single digits. Revenue growth collapsed from 59% to 9% in a single year, and management explicitly warned investors — I'm quoting the Co-CEO — that 'simple linear projection might not be a good way to project future performance.' Meanwhile, ROIC compressed 850 basis points in twelve months from 32.75% to 24.2%, and operating margin fell from 27.5% to 22.4% as management launched RMB 100 billion in merchant subsidies. Those subsidies aren't temporary investments — they're permanent margin transfers to prevent seller defection to Douyin and Kuaishou."

PART 4: VALUATION & RETURN COMPARISON

Buffett: "Let me consolidate the math into a single framework. I'm using the 12% historical growth rate from our data, capped because sustained growth above that level is rare, with exit multiples calibrated to each business's quality and predictability."

"The implied growth row reveals what the market actually expects. At 4.7× earnings, Mr. Market is pricing Crocs for negative 2% annual decline — essentially a slow death sentence. At 10×, the market expects Novo to grow at roughly 6%, half its historical rate. Every stock here is priced for significant disappointment. The investment question is which disappointment is least likely to materialize."

Pabrai: "Warren, your scenario table just validated the asymmetry I've been describing. In Crocs' bear case — growth cut in half to 6% — $100K still becomes $454K. That's 16% annualized in the worst scenario. Find me another stock on this table where the bear case delivers returns most fund managers can't achieve in their base case. The market is pricing in -2% growth while the international business — which management says has one-third the market share of established markets in China, India, Japan, Germany, and France — provides genuine runway for years. I don't need to resolve the fashion debate. The entry price is so low that even modest persistence of the business generates excellent returns."

Kantesaria: "Mohnish, your math is clean but your 12× exit multiple does the heavy lifting. The market has never sustained a premium multiple on Crocs because next year's earnings might be half this year's — that's what fashion risk means in practice. But I'll grant the implied growth analysis is revealing for every name on this table. At 9.5× earnings, the market implies 5% growth for Euronet — a company that has compounded at 10% for 14 years with management guiding 10-15% EPS growth for 2026. The FCF yield at today's price works out to roughly 17%, nearly four times the 4.3% risk-free rate. That's the kind of spread where back-of-envelope math tells you the opportunity is real even without a precise model."

Munger: "Dev, you keep gravitating toward Euronet, but let me bring us back to what's obvious rather than what requires specialized analysis. Novo at 10× with the market implying 6% growth is the widest gap between expectations and reality on this table. The obesity market is expanding over 30% annually. Wegovy launched in 35 new countries last year with 134% international sales growth. The denominator is barely scratched. The last time I saw this kind of disconnect between market pricing and operating trajectory was Bank of America at $5 during the financial crisis — the market was pricing in permanent impairment while the franchise was fundamentally intact. I'd rather own the obviously mispriced great business than the cleverly underpriced decent one."

Tepper: "Charlie, Novo's setup is compelling, but PDD offers a structural floor that pharma can't match. That $58 billion cash pile — 40% of market cap — means if I'm completely wrong about growth, I still own cash at a discount. If tariff changes kill Temu entirely, the domestic business earns approximately $10 billion annually on zero capital, trading at roughly 8× those domestic earnings net of cash. The market embeds a double catastrophe — Temu death and domestic margin collapse — that requires both hemispheres of the business to fail simultaneously. That's not a quality thesis, it's a mispricing thesis, and those are the setups where I earn my keep."

PART 5: RISKS, PRE-MORTEM & SIGNPOSTS

Buffett: "Before anyone gets comfortable, let's run a pre-mortem. Assume each stock lost 50% by 2029. Write the obituary — what specifically went wrong?"

Pabrai: "I'll write Crocs' obituary. It's 2029 and the stock sits at $38. A direct-to-consumer comfort brand backed by LVMH launched in 2027 and captured the healthcare worker segment that anchored Crocs' daily-wear positioning. North America revenue decline accelerated from -7% to -18% over three consecutive years. HEYDUDE — which management stubbornly refused to divest — consumed another $400 million in restructuring. China growth stalled at 12% market share as local competitors flooded the clog category with $8 alternatives manufactured in the same Vietnamese factories."

Prasad: "PDD's obituary is equally specific. It's 2029, trading at $48. Beijing imposed a 3% transaction tax on platform companies in late 2027 under its 'common prosperity' agenda, compressing operating margins from 22% to 12% overnight. Simultaneously, the U.S. and EU eliminated de minimis exemptions, converting Temu from profitable to cash-burning. The $58 billion cash pile — the primary bull argument — eroded to $20 billion funding international losses and a failed warehousing pivot. Management returned nothing to shareholders through the entire period."

Kantesaria: "I'll represent the Novo bears. It's 2029, NVO trades at $18. CagriSema's Phase 3 data showed only marginal superiority over tirzepatide, and the FDA demanded additional cardiovascular safety studies, delaying approval until 2029. Lilly's oral tirzepatide meanwhile captured 45% of new prescriptions. The DKK 180 billion manufacturing build-out became partially stranded — factories running at 40% utilization while DKK 131 billion in debt triggered two credit downgrades. Gross margins compressed to 72% as Novo slashed prices to compete."

Vinall: "Since I'm advocating for Euronet, let me write its failure narrative honestly. It's 2029, stock at $33. Wise and Remitly captured 60% of digital remittance volume, compressing Ria's segment margins below breakeven. The EU implemented a 1% cap on ATM foreign exchange spreads — destroying the highest-margin revenue line in EFT. And the settlement liquidity machinery — $8 billion in gross annual debt cycling on a $3 billion company — suffered a three-day disruption during a European banking stress event, triggering emergency credit draws and a confidence collapse. Michael Brown retired at 72, and his successor lacked the institutional relationships to stabilize the business."

Buffett: "Each of those obituaries is frighteningly plausible, which is exactly the exercise's value. Now give me signposts — concrete, measurable conditions that would change your position."

Munger: "If Novo's U.S. GLP-1 volume share drops below 45% for two consecutive quarters — currently around 55% — I'd reconsider. That would signal structural share loss rather than temporary supply dynamics, and I'd rotate toward Euronet if its ROIC simultaneously climbed above 15%."

Pabrai: "If Crocs' adjusted operating margin falls below 18% for two consecutive quarters — down from the current 22.3% — the entry multiple can no longer protect me. That's my exit threshold. Conversely, if HEYDUDE revenue stabilizes above flat growth, I'd add aggressively because the market prices in permanent decline for that segment."

Kantesaria: "If Euronet's money transfer segment posts two consecutive quarters of positive constant-currency growth while operating margins hold above 12%, the digital transition is working rather than destroying value. If that segment instead declines 5%+ for two quarters, I'd exit entirely."

Vinall: "If Novo's CapEx drops below DKK 50 billion annually while revenue exceeds DKK 350 billion — signaling the manufacturing build-out is complete and cash flow is inflecting — I'd rotate from Euronet to NVO. That FCF inflection point is what makes a $172 billion market cap suddenly look cheap."

PART 6: INVESTOR PICKS

🦅 Buffett's Pick — Novo Nordisk A/S (NVO): "Among these four, Novo is the only business where I can sketch the earnings in 2036 in ink rather than pencil. The biological compulsion to keep injecting is a switching cost more powerful than any contract or brand loyalty — as Charlie described, stopping means regaining 25 kilograms. Yes, Lilly is formidable, but two companies splitting a market growing 30%+ annually while serving fewer than 2% of eligible patients is not a zero-sum fight — it's a land rush. At 10× earnings, the market prices this like a mature utility while the underlying demand curve is barely past the first inning. I'd rather own the highest-quality business in this room at a fair price than the cheapest business at a price that seems wonderful."

🦉 Munger's Pick — Novo Nordisk A/S (NVO): "I'll add the inversion Warren skipped. What would make me lose money on Novo at 10× earnings? I'd need the global obesity epidemic to reverse — no epidemiologist projects that. I'd need GLP-1 therapy replaced by a superior treatment class — nothing credible exists in any pipeline. I'd need both Novo and Lilly to simultaneously destroy pricing — irrational in a duopoly. When I cannot construct a plausible permanent-loss scenario at this multiple, that's a fat pitch. The market is treating temporary competitive discomfort as permanent impairment — the same error it made with Moody's after the financial crisis."

🎯 Kantesaria's Pick — Euronet Worldwide Inc (EEFT): "None of these four fits my ideal framework — I want mandatory-checkpoint monopolies, and this table doesn't have one. But Euronet's payment infrastructure across 40 countries comes closest to the kind of position I look for. The FCF yield is roughly 17% against a 4.3% risk-free rate — four times the treasury on the back of an envelope. Revenue has compounded for 14 consecutive years while Brown has funded $1.6 billion in buybacks entirely from operations, with no dilutive acquisitions and no empire-building. The Dandelion settlement network — having signed Citi, HSBC, and Commonwealth Bank — provides optionality I'm not paying for. I'm compensated for the ambiguity at this price."

🦁 Tepper's Pick — PDD Holdings Inc (PDD): "I don't need PDD to be great — I need it to be mispriced, and $58 billion in cash on a $145 billion market cap tells me the market is pricing in catastrophe while the smartest China-focused investors on the planet are accumulating. If Temu dies completely, the domestic Pinduoduo business still earns $10+ billion annually on zero invested capital at roughly 8× net-of-cash earnings. If Temu survives in any geography, the upside is substantial. This isn't a quality bet — it's a sentiment bet with a massive cash floor, and those are the setups that have defined my best returns over three decades."

📚 Vinall's Pick — Euronet Worldwide Inc (EEFT): "Among these four, Euronet fits my framework on every dimension: founder-led, under $5 billion market cap, 17% FCF-per-share compounding, and clearing my 15% return hurdle without heroic assumptions. The EFT segment's transformation from ATM ownership to software-driven merchant acquiring — with segment EBITDA growing 32% — demonstrates a moat that is widening, not just wide. Brown has run this company through the dot-com crash, the financial crisis, and a pandemic that shuttered European tourism for two years, and the business never posted a losing year outside COVID. At 9.5× earnings, I'm paying a distressed multiple for demonstrated resilience."

🔥 Pabrai's Pick — Crocs Inc (CROX): "At $4.5 billion market cap and 4.7× earnings, Crocs is the only stock on this table where the 3:1 asymmetric payoff is mathematically straightforward. As the scenario table showed, even the bear case — growth halved — delivers 16% annualized returns, because the starting multiple is so compressed that time is on my side regardless. Warren's Coach parallel is fair, but Coach traded at 15× when it unraveled — not 4.7×. At this price, I'm buying the cash flow stream and getting the brand, the international expansion, and the China runway for free. NVO and PDD both fail my market cap threshold — at $172 billion and $145 billion respectively, the math for 3:1 upside requires valuations that have never existed for those categories."

🌿 Prasad's Pick — Novo Nordisk A/S (NVO): "My framework asks whether a business can survive and thrive across multiple economic cycles, and Novo's track record answers that question more convincingly than anything else on this table. Fourteen consecutive years of ROIC above 42% — through patent anxieties, competitive entries, pricing scandals, and a global pandemic — is survival fitness that neither Crocs, nor Euronet, nor PDD can demonstrate. Crocs nearly went extinct within memory. PDD has never been tested through a downturn. Euronet's ATM business faces genuine secular headwinds from mobile banking. Novo's demand is driven by biology — obesity rates are accelerating globally, not retreating — and that provides the slow-change environment where competitive advantages compound rather than erode."

PART 7: THE VERDICT

Vote Count:

• NVO: 3 votes (Buffett, Munger, Prasad)

• EEFT: 2 votes (Kantesaria, Vinall)

• CROX: 1 vote (Pabrai)

• PDD: 1 vote (Tepper)

• Total: 7 votes

🏆 Winner: Novo Nordisk A/S (NVO) — 3 votes

🥈 Runner-up: Euronet Worldwide Inc (EEFT) — 2 votes

⚠️ Dissent: Pabrai rejected NVO and PDD on market cap grounds (both exceed his $100B ceiling), choosing instead the mathematically optimal asymmetric bet at Crocs. Tepper dismissed the quality debate entirely, treating PDD as a pure mispricing play backed by $58 billion in cash.

The Swing Vote: Prasad was the decisive third vote for NVO. He seriously considered Euronet's 32-year founder story and payment infrastructure durability — both align with his evolutionary survival framework. What ultimately separated them was the ROIC gap: Novo's 43% versus Euronet's 10% demonstrated a level of capital efficiency fitness that Euronet couldn't match. Had Euronet's ROIC been above 20%, Prasad says he would have switched.

Conviction Spectrum: Buffett and Munger were locked in from the opening exchange — the biological lock-in argument was immediately decisive for both. Pabrai was equally certain in the opposite direction — at 4.7×, the asymmetric math overwhelmed all quality concerns. Kantesaria and Vinall both agonized — neither views Euronet as an ideal holding, but it was the least-bad fit for their respective frameworks. Tepper was the most detached, treating his PDD position as a tactical trade rather than a conviction investment.

Scenario Sensitivity: If Novo's U.S. GLP-1 volume share drops below 45% for two quarters while Crocs' international revenue growth accelerates above 15%, the vote likely shifts to 2-2-2-1, with Prasad moving toward Euronet's demonstrated resilience over Novo's deteriorating competitive position.

The question we couldn't settle: Will Novo Nordisk's DKK 180 billion manufacturing build-out become a durable competitive moat or partially stranded capacity? If CagriSema delivers strong Phase 3 data in late 2026 and CapEx normalizes by 2028, NVO at 10× was the buy of the decade. If Lilly's pipeline proves superior while Novo carries DKK 131 billion in debt against underutilized factories, the investment case unravels. Watch two specific data points: CagriSema Phase 3 readouts expected in late 2026, and Novo's CapEx guidance for fiscal 2027. Those numbers will answer the question this council couldn't.

Buffett: "Every investment decision ultimately comes down to one question: what can't change? Technology changes, fashion changes, regulation changes, management changes. But 890 million people needing treatment for a chronic condition — that's biology. And biology is the one force that doesn't read the news."